1 / 2

Chronic Venous Insufficiency Market

Chronic Venous Insufficiency refers to lower extremity edema, skin trophic changes, and discomfort secondary to venous hypertension. Chronic venous insufficiency pathophysiology is either due to reflux or obstruction of venous blood flow. Chronic venous insufficiency can develop from the protracted valvular inadequacy of superficial veins, deep veins, or perforating veins that combine them.

Télécharger la présentation

Chronic Venous Insufficiency Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chronic Venous Insufficiency refers to lower extremity edema, skin trophic changes, and discomfort secondary to venous hypertension. Chronic venous insufficiency pathophysiology is either due to reflux or obstruction of venous blood flow. Chronic venous insufficiency can develop from the protracted valvular inadequacy of superficial veins, deep veins, or perforating veins that combine them. Chronic Venous Insufficiency Signs and Symptoms The most common Chronic Venous Insufficiency symptoms are tight feeling in calves, painful legs, swelling in legs or ankles, painful leg cramps or muscle spasms, skin changes, varicose veins, leg ulcers, etc. Chronic Venous Insufficiency Epidemiology Chronic venous ulcers are painful and debilitating. Nearly 60% develop phlebitis, which often progresses to deep vein thrombosis in more than 50% of patients. The venous insufficiency can also lead to acute hemorrhage. Surgery for Chronic venous insufficiency remains inadequate despite the availability of numerous procedures. As per the study conveyed by Owayed Al Shammeri et al. (2014), Chronic Venous Insufficiency usually affects lower limbs with a prevalence fluctuating between 25–40% and 10–20% in women and men, respectively. The annual incidence is 2–6% in women and 1.9% in men. As per the study conducted by José- Román Escudero Rodríguez et al. (2013), the greater the age, the higher the prevalence and the more advanced the chronic venous ulcers. 99% of the patients required some form of treatment, with a more significant proportion among women. Sclerotherapy, endothermal ablation, or surgery was needed by 4% of the patients. Chronic Venous Insufficiency Treatment Options Chronic venous insufficiency is not a benign disorder and carries enormous morbidity. Without correction, the condition is progressive. Venous ulcers are apparent and very difficult to treat. Patients with chronic venous insufficiency should be treated based on the severity and nature of the disease. The treatment’s purpose includes reducing discomfort and edema, stabilizing skin appearance, removing painful varicose veins, and healing ulcers. Most patients should initially be treated conservatively with leg elevation, exercise, weight management, and compression therapy. Chronic Venous Insufficiency Market To meet the current unmet needs of chronic venous insufficiency, companies like Verigraft, SerenaGroup, and others are developing therapies to treat this indication. The existing pipeline for Chronic Venous Insufficiency has many vital products. The Chronic Venous Insufficiency

  2. market dynamics are expected to change in the coming years due to the diagnosis methodologies, incremental healthcare spending across the world, and the anticipated launch of many therapies during the forecast period. The factors that shall expedite the growth of the Chronic Venous Insufficiency market include increasing awareness about available treatments during the forecast period (2019–2030). Overall, the increasing Prevalence, disease awareness, and promising emerging pipeline therapies will drive the market size forward during the forecast period. A better understanding of disease pathogenesis will also contribute to developing innovative therapeutics for Chronic Venous Insufficiency.

More Related